Table 1.
Characteristics of the 533 GC patients enrolled into this study
| Variables | Total n (%) | Events n (%) | Median GC-specific OS (95% CI) (mo) | P value |
|---|---|---|---|---|
| Age (yr) | ||||
| ≤ 65 |
380 (71.3) |
178 (46.8) |
51.7 (39.7-63.7) |
< 0.001 |
| > 65 |
153 (28.7) |
100 (65.4) |
28.0 (21.6-34.4) |
|
| Gender | ||||
| Male |
389 (73.0) |
192 (49.4) |
39.7 (29.9-49.5) |
0.019 |
| Female |
144 (27.0) |
86 (59.7) |
28.0 (17.9-38.1) |
|
| Cancer site | ||||
| Upper third |
156 (29.3) |
80 (51.3) |
32.6 (25.9-39.3) |
0.004 |
| Middle third |
119 (22.3) |
61 (51.3) |
38.9 (9.4-68.4) |
|
| Lower third |
222 (41.7) |
112 (50.5) |
42.1 (34.2-49.9) |
|
| Whole stomach |
36 (6.8) |
25 (69.4) |
13.2 (10.1-16.3) |
|
| Pathological type | ||||
| Adeno WD/ID |
131 (24.6) |
59 (45.0) |
42.1 (29.9-54.2) |
0.212 |
| Adeno PD/UN |
299 (56.1) |
160 (53.5) |
34.9 (27.5-42.4) |
|
| Signet ring/mucious Ca |
85 (15.9) |
49 (57.6) |
28.0 (10.9-45.1) |
|
| Others |
18 (3.4) |
10 (55.6) |
33.7 (20.0-47.5) |
|
| Surgery type | ||||
| Proximal gastrectomy |
169 (31.7) |
82 (48.5) |
35.9 (20.5-51.3) |
< 0.001 |
| Distal gastrectomy |
268 (50.3) |
128 (47.8) |
46.6 (38.1-55.1) |
|
| Total gastrectomy |
96 (18.0) |
68 (70.8) |
17.4 (11.3-23.4) |
|
| Resection type | ||||
| Palliative resection |
11 (2.1) |
11 (100.0) |
9.8 (8.0-11.6) |
< 0.001 |
| Curative resection |
522 (97.9) |
267 (51.1) |
38.9 (31.8-46.0) |
|
| Other organ resection (n) | ||||
| 0 |
507 (95.1) |
256(50.5) |
39.3 (32.5-46.0) |
< 0.001 |
| 1 |
14 (2.6) |
11 (78.6) |
24.1 (9.6-38.7) |
|
| 2 |
8 (1.5) |
7 (87.5) |
12.4 (2.7-22.2) |
|
| ≥ 3 |
4 (0.8) |
4 (100.0) |
13.6 (2.7-24.4) |
|
| HIPEC | ||||
| No |
505 (94.7) |
251 (49.7) |
39.7 (32.4-47.0) |
< 0.001 |
| Yes |
28 (5.3) |
27 (96.4) |
13.4 (9.6-17.2) |
|
| LN status | ||||
| N0 |
172 (32.3) |
51 (29.7) |
67.3 (59.8-74.8) |
< 0.001 |
| N1 |
112 (21.0) |
57 (50.9) |
35.9 (26.8-45.0) |
|
| N2 |
143 (26.8) |
86 (60.1) |
27.0 (19.9-34.1) |
|
| N3 |
106 (20.0) |
84 (30.5) |
14.4 (12.0-16.8) |
|
| Tumor invasion | ||||
| T1 |
25 (4.7) |
3 (12.0) |
75.4 (66.4-84.4) |
< 0.001 |
| T2 |
85 (15.9) |
19 (22.4) |
72.7 (62.2-83.2) |
|
| T3 |
2 (0.4) |
1 (50.0) |
29.1 (10.7-47.4) |
|
| T4a |
332 (62.3) |
187 (56.3) |
33.0 (26.6-39.4) |
|
| T4b |
89 (16.7) |
68 (76.4) |
14.8 (10.8-18.9) |
|
| Distant metastases | ||||
| No |
478 (89.7) |
224 (46.9) |
42.5 (34.6-50.4) |
< 0.001 |
| Yes |
55 (10.3) |
54 (98.2) |
10.6 (9.0-12.1) |
|
| TNM staging | ||||
| Stage I |
79 (14.8) |
8 (10.1) |
85.2 (76.1-94.3) |
< 0.001 |
| Stage II |
100 (18.8) |
35 (35.0) |
53.9 (46.6-61.3) |
|
| Stage IIIA |
80 (15.0) |
38 (47.5) |
40.0 (21.7-58.3) |
|
| Stage IIIB |
116 (21.8) |
67 (57.8) |
28.0 (14.9-41.1) |
|
| Stage IIIC |
117 (22.0) |
90 (76.9) |
14.8 (10.6-19.1) |
|
| Stage IV |
41 (7.7) |
40 (97.6) |
11.1 (9.7-12.4) |
|
| Postoperative SAE | ||||
| No |
458 (85.9) |
205 (44.8) |
49.8 (32.5-67.0) |
< 0.001 |
| Yes |
75 (14.1) |
73 (97.3) |
14.8 (10.0-19.6) |
|
| Systemic chemotherapy (cycles) | ||||
| 0 |
217 (40.7) |
128 (59.0) |
26.3 (19.2-33.4) |
0.001 |
| 1 to 6 |
302 (56.7) |
142 (47.0) |
51.7 (36.6-66.9) |
|
| > 6 |
14 (2.6) |
8 (57.1) |
37.8 (16.9-58.7) |
|
| IP chemotherapy | ||||
| No |
521 (97.7) |
267 (51.2) |
37.0 (29.8-44.2) |
0.003 |
| Yes | 12 (2.3) | 11 (91.7) | 11.1 (7.0-15.1) | |
GC: gastric cancer; GC-specific OS: gastric cancer-specific overall survival; Adeno WD/ID: well differentiated or intermediately differentiated adenocarcinoma; Adeno PD/UN: poorly differentiated or undifferentiated carinoma; Signet ring/mucious Ca: Signet ring cell carcinoma or mucious adenocarcinoma; HIPEC: hyperthermic intraperitoneal chemotherapy; LN status: lymph node status; SAE: serious adverse event; IP chemotherapy: intraperitoneal chemotherapy.